glp 1 reta Retatrutide Weight Loss Reta (RUO) | GIP/GLP-1/GCG Agonist

Evidence-based results Better energy, confidence, and overall wellbeing A pathway to sustainable, long-term health Results What patients achieve 0% Reach their weight goals Average weight loss in first three months 0% Report improved energy Patients report sustained energy throughout treatment 0 Week average to first results Most see meaningful changes by week twelve Results That Speak For Themselves Results What patients achieve Your practitioner stays connected throughout your treatment Messaging access to your practitioner Direct line to the doctor who knows your case LEARN MORE Dose adjustments when you need them No waiting rooms, no delays in your care LEARN MORE Community Support Scheduled visits to track progress and refine your plan LEARN MORE

10.1038/sj.jidsymp.5650007 21 KhatifH.BazziH

Cao J, Belousoff MJ, Gerrard E, Danev R, Fletcher MM, Dal Maso E, et al

Chen H, Liu J, Kaniskan H, Wei W, Jin J

What is your shipping protection

B: Peginterferon alfa-2b, 1 g/kg subcutaneously once weekly, or Peginterferon alfa-2a, 135 g subcutaneously once weekly plus Ribavirin, 200800 mg/day in two divided does starting with low dose and increasing gradually C: Controversial: Standard interferon (2a or 2b) 3mU three times weekly, or Pegylated interferon alfa-2b, 1 g/kg/week, or Pegylated interferon alfa-2a, 135 g/kg/week Ribavirin in markedly reduced daily dose